We Are Family: Why Recent Deals Show China And US Won’t Part Long
Executive Summary
Recent deals linking Chinese and foreign firms indicate new and bolder views on China’s prospects for cutting-edge oncology and rare disease treatments, helped by recent regulatory changes, but a mix of factors is still at play, veteran executives say.
You may also be interested in...
Deal Watch: Takeda Continues Shire Merger Prep With Out-License Of Relugolix Rights
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
US FDA Right To Try Policy: For Now, Defer Questions To Sponsors, Bill Text
Agency tells staff that it should refer patient questions about the law to the drug sponsor, while sponsors should be told to read the statute if they inquire about it.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.